The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK
暂无分享,去创建一个
[1] E. Barr,et al. Quadrivalent human papillomavirus vaccine. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] E. Myers,et al. Abnormal Outcomes Following Cervical Cancer Screening: Event Duration and Health Utility Loss , 2007, Medical decision making : an international journal of the Society for Medical Decision Making.
[3] C. Wheeler,et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials , 2007, The Lancet.
[4] Erik J. Dasbach,et al. Model for Assessing Human Papillomavirus Vaccination Strategies , 2007, Emerging infectious diseases.
[5] S Gallivan,et al. Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK , 2006, British Journal of Cancer.
[6] G. Krogh,et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up , 2006, British Journal of Cancer.
[7] Elamin H Elbasha,et al. Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. , 2006, Epidemiologic reviews.
[8] D. Wiley,et al. Human papillomavirus: the burden of infection. , 2006, Obstetrical & gynecological survey.
[9] W. Edmunds,et al. Modeling Future Changes to the Meningococcal Serogroup C Conjugate (MCC) Vaccine Program in England and Wales , 2006, Human vaccines.
[10] A. Galvani,et al. Vaccination against multiple HPV types. , 2005, Mathematical biosciences.
[11] Cosette M Wheeler,et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.
[12] N. Kiviat,et al. Development and duration of human papillomavirus lesions, after initial infection. , 2005, The Journal of infectious diseases.
[13] Xavier Castellsagué,et al. Against which human papillomavirus types shall we vaccinate and screen? the international perspective , 2004, International journal of cancer.
[14] P. Langley,et al. The costs of treating external genital warts in England and Wales: a treatment pattern analysis , 2004, International journal of STD & AIDS.
[15] Z. Philips,et al. An evaluation of liquid-based cytology and human papillomavirus testing within the UK cervical cancer screening programme , 2004, British Journal of Cancer.
[16] J Chilcott,et al. Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis. , 2004, Health technology assessment.
[17] David Parkin,et al. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. , 2004, Health economics.
[18] W. Edmunds,et al. Economic Evaluation of Vaccination Programs: The Impact of Herd-Immunity , 2003, Medical decision making : an international journal of the Society for Medical Decision Making.
[19] N. Kitchin,et al. Universal hepatitis B vaccination of UK adolescents: a feasibility and acceptability study. , 2002, Communicable disease and public health.
[20] Almut Scherer,et al. Mathematical models of vaccination. , 2002, British medical bulletin.
[21] Mark A. Miller,et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. , 2000, JAMA.
[22] D J Nokes,et al. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. , 1999, Statistics in medicine.
[23] D. Whynes,et al. Stage-specific treatment costs for cervical cancer in the United Kingdom. , 1998, European journal of cancer.
[24] M. Botcherby,et al. Changes in HPV infection in patients with anogenital warts and their partners. , 1993, Genitourinary medicine.
[25] Bob Erens,et al. National Survey of Sexual Attitudes and Lifestyles II: reference tables and summary report. , 2003 .